abacavir sulfate tablet, film coated
mylan institutional inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg - abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)]. - with moderate or severe hepatic impairment [see use in specific populations (8.6)] . there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta cong
abacavir and lamivudine tablet, film coated
avkare - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients:abacavir and lamivudine tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions ( 5.1)]. who have the hla-b*5701 allele [see warnings and precautions ( 5.1)]. - with prior hypersensitivity reaction to abacavir [see warnings and precautions ( 5.1)] or lamivudine. with prior hypersensitivity reaction to abacavir [see warnings and precautions ( 5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations ( 8.7)]. with moderate
abacavir and lamivudine tablets usp 600 mg/300 mg oral tablet 600/300
laurus labs limited, india - abacavir , lamivudine tablets usp 600 mg/300 mg - oral tablet - 600/300
triumeq dolutegravir (as sodium) 50 mg/abacavir (as sulfate) 600 mg/lamivudine 300 mg tablet bottle
viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg; dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in triumeq.
abacavir and lamivudine- abacavir sulfate and lamivudine tablet, film coated
prasco laboratories - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine tablets during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for b
abacavir/lamivudine viatris abacavir (as sulfate)/lamivudine 600 mg/300 mg film-coated tablet blister pack
alphapharm pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.78 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; silicified microcrystalline cellulose; purified talc; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - abacavir/lamivudine viatris tablets are a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine viatris is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.
abacavir/lamivudine mylan 600 mg/300 mg film-coated tablets
mcdermott laboratories ltd., t/a gerard laboratories - abacavir; lamivudine - film-coated tablet - 600mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir
triumeq
glaxo smith kline (israel) ltd - abacavir as sulfate; dolutegravir as sodium; lamivudine - film coated tablets - dolutegravir as sodium 50 mg; abacavir as sulfate 600 mg; lamivudine 300 mg - lamivudine and abacavir and dolutegravir - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents above 12 years of age weighing at least 40 kg.before initiating treatment with abacavir-containing products, screening for carriage of the hla-b*5701 allele should be performed in any hiv-infected patient, irrespective of racial origin. abacavir should not be used in patients known to carry the hla-b*5701 allele.
epivir 150 mg
glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 150 mg - lamivudine - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children. 25/10/2018 בקשה לשינוי משטר מינון
dolutegravir sodium, emtricitabine and tenofovir alafenamide tablets 50/200/25 mg
hetero laboratories limited, india - dolutegragravir, emtricitabine , tenofovir alafenamide tablets - tablets - 50/200/25 mg